CAR T-cell therapy (Cell Design Labs/Kite Pharma)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCAR T-cell therapy (Cell Design Labs/Kite Pharma)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCell Design Labs Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCell Design Labs IncKite Pharma Inc
Active IndicationsN/A
Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A
Related LinksN/A